Expert in

Immunotherapy,: DCs, TILs, CAR-T, tTcR. Immunochemestry.. Immunodeficiencies..

Training

• MD, PhD in Medicine. University of Barcelona (UB), 1988 & 1994.
• Specialist in Immunology and its Specific Areas. Hospital Clínic de Barceloa, 1993.

Research (Summary)

• Group Leader at FCRB-IDIBAPS: Immunogenetics and immunotherapy in autoinflammatory and immune responses
• 239 articles in journals with IF (3 national and 234 international papers); 189 papers in total
• Total IF: 722,060
• Publications in last 5 years: 29 -› summatory impact factor: 172,952
• Communications: 90 National + 137 International Congresses.
• H-Index: 52
• Sum of Times Cited (without self-citations): 12887
• Average per item: 28.71
• Patents: 10

Senior consultant in Paediatric haematology
Head of the Leukaemia and Lymphoma Department and CAR T-cell Unit. Pediatric Cancer Center Barcelona.

Expert in

Pediatric acute lymphoblastic leukaemia. Immunotherapy in acute leukaemia

Training

• Doctoral thesis: "Clinical characterisation and prognostic factors in subgroups of paediatric patients with acute lymphoblastic leukaemia at a high risk of relapse". University of Barcelona, 2013.
• Specialist in Haematology and Haemotherapy, Hospital Clínic Barcelona, 1995.
• Bachelor's degree in Medicine and Surgery, University of Barcelona, 1994.

International experience

• Placement in the Cancer Immunotherapy department of the Children's Hospital of Philadelphia (United States), 2014.
• Placement in the Leukaemia and Lymphoma department of the Saint Jude Children's Research Hospital (United States), 2001.

Josu de la Fuente is a Consultant Haematologist at Imperial College Healthcare NHS Trust and Professor of Practice (Cellular and Gene Therapies) of Imperial College London. He was appointed Director of the Paediatric Blood & Marrow Transplant Programme in 2006, specialising in transplantation for haemoglobinopathies and bone marrow failure, and being innovative in the use of alternative donors. He is the vice-chair of Paediatric Diseases Working Party of EBMT, a member of the steering committee of the BMT CTN 1507 trial Co-Director of the Vanderbilt Global Consortium for a Cure. He is an investigator and in the steering committee of a several gene therapy trials in sickle cell disease and thalassaemia.

After an initial period in adult medicine, Professor de la Fuente completed his general training in paediatrics in different hospitals in London and following membership of the Royal College of Paediatrics and Child Health, he trained in haematology at Imperial College and Great Ormond Street Hospital achieving membership of the Royal College of Pathologists. During this time, he developed an interest in red cell disorders, bone marrow failure and transplantation, including a period of basic research in human developmental haemopoiesis as an MRC Clinical Research Fellow leading to a PhD. He has also developed a unique clinical and research programme for Diamond Blackfan anaemia patients.

My main interests include novel therapies, in particular targeted, cellular and gene therapies and ensuring the needs of rare anaemias and bone marrow failure are represented, with particular attention to Diamond Blackfan anaemia.

• Deputy Chairman, Pediatric Hematology Oncology Department
  King Abdullah Specialist Children Hospital, King Abdulaziz Medical City, Ministry of National Guard, Riyadh, Saudi Arabia
• Associate Professor
  King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
• Section Head, Pediatric Hematopoietic Stem Cell Transplant division
  King Abdullah Specialist Children Hospital, Ministry of National Guard, Riyadh
• Consultant, Pediatric Hematology Oncology
  King Abdullah Specialist Children Hospital, Ministry of National Guard, Riyadh
• Chairman of Pediatric and Adult Stem cell Transplant Quality management Committee
  King Abdullah Specialist Children Hospital, Ministry of National Guard, Riyadh
• Program Director of Pediatric Hematology Oncology Fellowship
  King Abdullah Specialist Children Hospital, Ministry of National Guard, Riyadh
• Section Head, Pediatric Hematology
  King Abdullah Specialist Children Hospital, Ministry of National Guard, Riyadh

Chief of Blood and Marrow Transplantation, joined Children’s National Hospital from Children’s Memorial Hospital in Chicago

where he served as a member of the Stem Cell Transplant Program staff and as the Director of the Chronic Graft-versus-Host Disease Clinic. He has lectured widely on GvHD/BMT in Europe, Latin America, and the United States. He got his Bachelor of Science from Yale University, his medical degree from Tufts University, and a Masters in Clinical Investigation from Johns Hopkins School of Hygiene and Public Health.

MD, PhD

Assistant Professor of Pediatrics
Division of Oncology
Cancer and Blood Diseases Institute
Cincinnati Children’s Hospital Medical Center

As a pediatric oncologist, he is specialized in treating pediatric leukemia and lymphoma, emphasizing the use of cellular therapy. Cellular therapy involves modifying a patient’s own cells or cells from a donor to fight disease. He was inspired by the strength and bravery of children going through cancer diagnosis and treatment.

I am a Professor in Paediatric Immunology and Haematopoietic Stem Cell Transplantation at the University of Newcastle upon Tyne and Honorary Consultant for the Northern Supra-Regional Bone Marrow Transplant Unit for SCID and related disorders, at the Great North Children’s Hospital, Newcastle upon Tyne, clinically qualified and active. I spent a year of post-doctoral studies working with Anne Durandy and Alain Fischer in the Necker Hospital in Paris and was involved in the discovery of Cytidine Deaminase one of the first genes to be discovered involved in class switch recombination and somatic hypermutation.

I have been a consultant in Newcastle for 19 years. I have pioneered Paediatric immunology research at the university. My research interests include immunoreconstitution following haematopoietic stem cell transplant for primary immunodeficiency, long-term outcomes of transplantation for primary immunodeficiency (and in particular, Chronic Granulomatous Disease and Severe Combined Immunodeficiency), DNA repair disorders and their appropriate treatment and Di George Syndrome. More recently, I have adapted new methods of T cell depletion for patients with primary immunodeficiency, and established extracorporeal photopheresis for the treatment of children with graft versus host disease. I have discovered important mechanistic insights relating to the action of extracorporeal photopheresis. I am exploring the use of defibrotide for treatment of non-VOD endothelial cell activation disorders post-HSCT.

Rabi Hanna, MD, is the director of the Pediatric Bone Marrow Transplantation at Cleveland Clinic Children's Hospital, Department of Pediatric Hematology

Dr. Hanna is board certified in pediatrics and pediatric hematology-Oncology. He earned his medical degree from Aleppo University Faculty of Medicine in Aleppo, Syria. His post-graduate training in USA includes a pediatric residency at Duke University Medical Center in Durham, North Carolina, and a pediatric hematology-oncology fellowship at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital in Seattle, Washington. His specialty interests include treatment of children with leukemia / Lymphoma and solid tumors that require Hematopoietic Stem Cell Transplantation to consolidate the treatment for their malignant disease, and he also very interested in treatment of inherited non-malignant disorders like primary immunodeficiency like SCID or other inherited metabolic diseases which Hematopoietic Stem Cell Transplantation could offer the potential to restore normal hematological and immunologic function.

Expert in

Neuroblastoma, Ewing sarcoma, Wilm's tumour, Rhabdomyosarcoma, brain stem glioma, Retinoblastoma. Translational research.

Training

• PhD in Medicine. Autonomous University of Barcelona (UAB), 2003.
• Pediatric specialist, Hospital Vall d’Hebron, 1995.
• Bachelor's Degree in Medicine. University of Barcelona, 1990.

International experience

• Memorial Sloan-Kettering Cancer Center, Molecular Pathology of Pediatric Tumors Fellowship. New York, USA. 1999 - 2001.
• The New York Hospital Cornell University and Memorial Sloan-Kettering Cancer Center Combined Fellowship Programs (peds Hem/Onc), New York, USA. 1996 - 1999.

Scientific activity

• Author of over 463 peer-reviewed articles and 6 book chapters in national and international publications. H-Index of 62.
• Mentored 13 PhD students
• Specialty Chief Editor in Frontiers in Oncology. Member of the Editorial Board of Cancers and Pediatric Blood & Cancer.

Chairperson, Director of Paediatric SCT program in Kuwait
Head of pediatric SCT unit in NBK Children’s Specialised Hospital

Committee head for Stem Cell and tissue principles and technical and administrative standards.

Head of committee for Central Policies for secondary and tertiary care, member of COVID-19 inspection team in MOH, Vice-president of SCD higher committee, president of Kuwait Paediatric association. Treasurer of Kuwait Thalassaemia league. Member of international bodies: EBMT, ISCT, ASTCT, ASHI, ARSHI. Graduated from Dublin, Ireland RCSI, double qualification for paediatrics (Kuwaiti board and MRCPCH), fellowship in paediatric haematology and SCT UK. Established the paediatric SCT in 2020, initiated the treatment of CCP in Kuwait 2020.Research interest in the field of benign haematology, thrombosis haemostasis and stem cell transplantation.

Professor of Clinical Pediatrics
Medical Director, BMT and Immune Deficiency
Cancer and Blood Disease Institute
Cincinnati Children’s Hospital Medical Center

He has been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.

As a bone marrow transplant physician, he believes that each patient is unique. he uses a cooperative approach to treatment, in which he is a partner with the treatment team, the patient and their family.

His research involves finding treatments for and prevention of viral infections in immunocompromised patients

Education

MBBS, DCH FRCPCH (UK), MSc Oncology University of Birmingham (UK) CCT(UK), Fellowship Bone Marrow Transplantation (UK)

Dr. Zainul Aabideen is a Consultant in Pediatric Hematology, Oncology and BMT based in the United Arab Emirates.

Having gained his medical degree at Calicut University in Kerala, India, followed by his Post Graduation in Pediatrics from the University of Mumbai, He moved to the United Kingdom in 2001 to undertake further training in these areas.

Clinical Lead & Consultant, Pediatric Hematology/Oncology/BMT at Yas Clinic/Abu Dhabi Stem Cell Center, Abu Dhabi

Dr. Mansi Sachdev is an accomplished medical consultant in Pediatric Hematology, Oncology, and Bone Marrow Transplant. Her impressive career began with an MBBS from Sri Devaraj Urs Medical College in India. She further honed her expertise through clinical and research fellowships at esteemed institutions such as St. Jude Children's Research Hospital and Penn State Milton S. Hershey Children's Hospital, focusing on Pediatric Bone Marrow Transplant and Cellular Therapy and Pediatric Hematology/Oncology and Stem Cell Transplant. Her clinical proficiency encompasses various aspects of Pediatric Hematology, Oncology, and Bone Marrow Transplant.

Beyond her clinical work, Dr. Sachdev has a prolific research background, specializing in areas such as childhood cancer, leukemia treatments, and stem cell transplantation. Her research findings have been presented at numerous conferences and published in prestigious medical journals.

As a dedicated professional, Dr. Mansi Sachdev continues to make significant contributions to pediatric healthcare and research. Her wealth of experience and unwavering commitment to children's well-being solidify her as a valuable asset in her field.

I am a Professor of Paediatric Immunology and Gene Therapy at UCL Great Ormond Street Hospital Institute of Child Health in London and lead the clinical stem cell gene therapy programme at Great Ormond Street Hospital. I’m a clinical academic leading an expanding number of gene therapy clinical trials for patients with immune deficiencies, haematological and metabolic disorders. My research is focused on developing novel therapies for immune system disorders using innovative gene modification techniques. I have extensive experience of translating, leading, and delivering first in human clinical trials and the commercialisation pathway. As an attending physician I oversees the clinical management of patients with immune deficiencies, including hematopoietic stem cell transplantation and maintain a strong interest in HLH disorders.

I am an elected board member of the European and American Societies of Gene and Cell Therapy, serve on the editorial board of several journals and grant review committees and hold an honorary position at Boston Children’s Hospital and Harvard Medical School. I have generated over £12M research income, have an H index of 37 and › 4700 citations.

Together with several ESID Colleagues, I co-founded the AGORA initiative (Access to Gene therapies fOr RAre disease) which brings together European academic developers and patient organisations, aiming to facilitate access to effective gene therapies for treatment of patients with ultra-rare diseases.

Dr Robert Chiesa graduated in Medicine at the University of Milan, Italy and then he trained in paediatric haemato-oncology and stem cell transplant in Monza, where he worked on several research projects related to new drugs in relapsed ALL.

After his specialization in Paediatrics, he worked 2 years at the San Raffaele Institute in Milan, where he published in the field of stem cell transplant in thalassaemia and stem cell gene therapy in primary immunodeficiencies.

He then moved to the Bone Marrow Transplant Department at Great Ormond Street Hospital in London, where he has led on a number of studies in malignant and non-malignant diseases.

He set up the radio-immunotherapy phase 1 and phase 2 study on the use of Yttrium-90 labelled anti-CD66 antibody as part of the conditioning regimen prior to transplant in high-risk malignancies.

He set up the first Treosulfan PK clinical trial in the UK. He is the principal investigator of a study on the use of Nomacopan in transplant-associated microangiopathy.

He led on large studies within the IEWP and Eurocord framework, on the outcome of stem cell transplant in chronic granulomatous disease and osteopetrosis. He led a large study on the outcome of stem cell transplant in cerebral adrenoleukodystrophy and he led the ALD-104 gene therapy study in the UK.

He has worked in the field of CAR-T cell therapy in B-lineage ALL and over the past few years, he has led with Professor Waseem Qasim the allogeneic CART programs in T-ALL and AML, as principal clinical investigator.

Dr Chiesa is the BMT Specialty Lead at Great Ormond Street Hospital and he has several publications in high impact journals such as the New England Journal of Medicine, Blood and Nature Medicine.

• Consultant pediatrician and Epiletologist
• Head of pediatric Neurology Unit
• A member of Kuwait league against Epilepsy, Kuwait association of pediatric
• Permanent delegate of Asian Ocean Child Neurology Association
• Member of International child Neurology Association

• Head of Immunology Unit and Transplant Lab - KCCC
• Director of Medical Laboratories AlRashid Allergic Diseases Center
• Program Director of Diagnostic and Investigative Immunology Program KIMS

Dr Nada Alshatti a clinician a with a deep expertise in diagnostic and investigative immunology. She serves as the Head of the Immunology and Transplant Lab at kuwait cancer control center and as the Director of Medical Laboratories at Al-Rashid Allergic Diseases Center. In addition, Dr Nada is the program director of the Diagnostic and Investigative Immunology Program at Kuwait Institute of Medical Specialization and and Elected Board member of Arabian Society of Histocompatibility and Immunogenetics ARSHI

contributing to the regional advancement in Immunogenomics and transplantation field

Prof. Jawdat is the Chairman of the department of Cellular Therapy Services, which includes the Saudi Stem Cell Donor Registry (SSCDR), Cord Blood Bank, Stem Cell and Cellular Therapy Laboratory at King Abdullah International Medical Research Center under the Ministry of the National Guard Health Affairs. She is a Senior Research Scientist and a Laboratory Consultant in the field of Immunology, certified by the American Board of Medical Laboratory Immunology D(ABMLI).

Prof. Jawdat is a Professor of Immunology at King Saud Bin Abdulaziz University for Health Sciences (KSAU). Prof. Jawdat is an active member of numerous professional societies including ISCT, ASHI, EMBT, SSBMT, ARSHI and SHIS. Furthermore, Dr. Jawdat is a WMDA Quality/ Accreditation Expert Reviewer, and FACT quality standard reviewer and inspector.

Prof. Jawdat is an active researcher, she has published two book chapters, more than 60 articles in peer reviewed journals, and more than 70 conference abstracts. Her area of research interest is immunology, specifically HLA and transplantation. She is currently engaged in immunotherapy projects and the production of (CAR-T Cell) that target antigens on tumor cells in order to treat cancer.

RD, MSc-MPH, PhD candidate

Digestive Disease Institute - Cleveland Clinic Abu Dhabi

Currently a PhD candidate at Lancaster University, Carla Daou holds a Bachelor’s degree in Nutrition and Dietetics from the Lebanese American University in Beirut, Lebanon and a Master’s degree in Public Health-Biostatistics and Epidemiology from Penn State University in Pennsylvania, United States. She started her career as a clinical dietitian at Clemenceau Medical Center Johns Hopkins affiliated, and then expanded her expertise as a research fellow at the Pennsylvania State Hershey Medical Center contributing to impactful nutrition and public health research. Carla was later appointed as a nutrition consultant at the Queen Rania Foundation for Education and Development where she helped create 2 massive open online courses on nutrition and health that were delivered to 9000 participants in the Middle East and North Africa. For the past six years, Carla has been with Cleveland Clinic Abu Dhabi, leading the Home Parenteral Nutrition service and specializing in the management of complex bariatric, gastrointestinal failure and transplant patients who require short- and long-term nutrition support, enteral and parenteral nutrition, guiding them from inpatient settings to home-based care. In addition to her clinical duties, she serves as a preceptor to numerous students and graduate trainees yearly, furthering her commitment to education and clinical excellence.

National Cancer Institute - Cairo University, Egypt.
National Bank of kuwait specialized childrens' hospital, kuwait.

Omar Shawky Arafah received the Master. and Medical Doctorate. degrees from Cairo University, Egypt, in 2010 and 2016, respectively.

In April 2016, he became consultant and lecturer at the Department of Pediatric Oncology, National Cancer Institute, Cairo University.

Also in 2016, he became a consultant of Pediatric Oncology in 57357 hospital (Children Cancer Hospital in Egypt - CCHE), the largest specialized pediatric oncology center in the middle east and even with the largeest number of serving beds across the pediatric oncology centers all over the world. The hospital is up to date in relevant knowledge, cooperating with the most recognized centers in the field, actively participating in research and equipped with the most recent running system technology, papreless work, having the most recent laboratory and imaging devices in the market and JCI accredited three times in a row.

He is the author or coauthor of more than 10 papers in international refereed journals and more than 20 national and international conference contributions.

He has given several talks at international conferences. His research interests cover several aspects across pediatric cancers, mainly in solid tumor research and neuro-oncology. He is the former CO - PI of pediatric germ cell tumors study team in CCHE hospital. He is supervising a collaberative work and research in the field of germ cell tumors with recognised professors from Dana-Farber hospital, USA.

He joined National Bank of Kuwait specialized childrens' hospital in April 2021 as a specialist in peditric solid tumors and neuro-oncology where he shares experiences and helps in enriching this rapidly evolving branch with state of art knowledge.

• Clinical and Biochemical Geneticist, Assistant Professor of Pediatrics at Pediatric Department, College of Medicine Kuwait University, Kuwait
• Consultant of Genetics and Metabolism, Farwaniya Hospital, Ministry of Health, Kuwait
• Consultant of Genetics and Metabolism, Kuwait Medical Genetics Center, Ministry of Health, Kuwait
• Adjunct Assistant Professor of Genetic Medicine, Johns Hopkins University School of Medicine, Maryland, USA

• Specializing in the management of hematologic malignancies & hematopoietic stem cell transplantation (HSCT).
• Director of the Adult HSCT Program at King Faisal Specialist Hospital & Research Center in Riyadh, Saudi Arabia

Dr Waleed Al-Herz is American Board certified in pediatrics and allergy & clinical immunology and currently is an associate Professor of Pediatrics at Kuwait University. . Dr Al-Herz was the founder and Ex-Chairman of the Faculty of Clinical Immunology and Allergy in the Kuwait Institute for Medical specialization. He is the founder of Kuwait National Primary Immunodeficiency Registry in 2006 and a Member of The International Union of Immunological Societies, Inborn Errors of Immunity Committee. Dr Al-Herz has more than 120 publications in peer-reviewed journals about primary immunodeficiencies and allergies. He was also awarded as best young researcher by Kuwait University, best scientific production by Kuwait Foundation for the Advancement of Sciences and distinguished researcher by Kuwait Medical Association. In addition, he is a member of the Editorial board and is a reviewer for major allergy and clinical immunology journals.

Dr. Mariam Salem is a highly motivated general pediatrics assistant registrar currently working in Jaber Al Ahmad Al Sabah Hospital. She is passionate about child health and well being, alongside quality improvement in healthcare in Kuwait. She will be starting her residency in the Kuwaiti Board of Pediatrics.

• MB, Bch, BAO Trinity College Dublin in Ireland
• Member of Sahabat Amal volunteer group, medically volunteered in Zanzibar and Kenya
• Volunteer staff in Kuwait Association for the care of Children in Hospital (KACCH) and Bayt Abdullah Children’s Hospice (BACCH)

MD, FRCPC, FAAP.

Pediatrician and Pediatric hematologist oncologist.

Dr. Muneera is a Pediatric hematologist oncologist currently working at NBK hospital for children’s cancer care in Kuwait.

Dr. Muneera completed her medical degree and achieved her certifications of Bachelors of Medical Sciences (BMSc), followed by Doctor of Medicine (MD) at Kuwait University.

She completed her pediatric residency training at McMaster University, Canada. She is a certified pediatrician by the Royal College of Physicians and Surgeons Canada and the American Academy of pediatrics.

Further, she completed her subspecialty training in pediatrics hematology oncology at University of California Irvine (UCI) / Children’s Hospital of Orange County (CHOC) in the United States.

Her research focus was on the management of PH- like leukemia with use of TKIs.

Her main area of interest lies in Quality Improvement & Patient Safety as well as medical education.

John M. Cunningham, MD, is an internationally known expert in the treatment and research of childhood cancers and blood diseases. He has particular expertise in treating leukemia, lymphoma, immunodeficiencies, sickle cell disease and thalassemia. He is a recognized leader in the field of pediatric stem cell transplantation and has developed novel uses for this life-saving treatment.

An active researcher, Dr. Cunningham is studying the biology and therapy of hemoglobinopathies, hematopoiesis and the leukemia stem cell, transcriptional mechanisms operative during the development of vertebrate organisms, and the development of clinical trials for the treatment of leukemia and genetic diseases. Over his distinguished career, Dr. Cunningham's research has received support from the National Heart, Lung, and Blood Institute, the American Society of Hematology, and other prominent scientific organizations. He is a member of the scientific council of the American Cancer Society, and a member of the editorial board of The Oncologist.

Dr. Cunningham is an accomplished author and has published more than 100 scientific articles, as well as several book chapters and invited reviews. He has served on the editorial board of the Journal of Biological Chemistry, and is a reviewer for Blood, Molecular and Cellular Biology, Cancer Research, and Genomics. A popular speaker, Dr. Cunningham has lectured at universities and scientific meetings around the world. Dr. Cunningham has also been selected as a top doctor by Chicago magazine and is an American Top Doctor.

Before joining the University of Chicago Medicine, Dr. Cunningham was a leader in the Division of Experimental Hematology and Bone Marrow Transplantation at St. Jude Children's Research Hospital in Memphis, Tenn.

James LaBelle, MD, PhD, provides care for children of all ages with cancer and blood diseases, including leukemia and lymphoma. In particular, Dr. LaBelle specializes in stem cell transplantation, replacing a patient's diseased bone marrow and immune system with healthy cells.

Dr. LaBelle's laboratory research focuses on understanding at a molecular level the reason why some pediatric cancers are resistant to therapy. He currently serves as the primary investigator on a study examining a critical network of proteins that regulate whether a malignant cell lives or dies. The normal signaling between these proteins often is disturbed in cancerous cells. Through this research, he hopes to identify novel cell death regulatory mechanisms in resistant hematopoietic malignancies and design effective strategies to overcome them. Dr. LaBelle's research is currently funded by the National Institutes of Health.

A dedicated mentor, Dr. LaBelle also received special recognition for teaching medical students, residents, and fellows about pediatric hematology, oncology and hematopoietic stem cell transplantation.

Rodaina Abu Joub is a Pediatric Stem Cell Transplant and Cellular Therapy Clinical Nurse Specialist and Program Team Leader at the Division of Stem Cell Transplant and Cellular Therapy, Nursing Services, KASCH in Riyadh. In her role as team leader, Miss Rodaina is responsible for overseeing the daily operations of the pediatric stem cell transplant and cellular therapy program, ensuring the implementation of the quality management plan, and effectively organizing the team based on the core pillars of nursing practice. She also serves as a key resource for nursing staff in the division.

She has more than 20 years of experience in the pediatric stem cell transplant and cellular therapy fields, Miss Rodaina has advanced knowledge and skills in clinical care, evidence-based practice, education, and leadership.

She provides clinical expertise across the entire stem cell transplant, CAR-T and gene therapy process. A highly competent and proactive professional, and actively involved in research.

Sara Ghorashian qualified from Oxford University and undertook haematology training at the Hammersmith and Royal Free Hospitals. She obtained a PhD at University College London (UCL) in the use of gene-engineered T cells for cancer immunotherapy. More recently, her post-doctoral studies at the UCL Great Ormond Street Institute of Child Health involved translation of CD19CAR T cells as therapy for childhood acute lymphoblastic leukaemia (ALL) from bench to bedside. Her research interests are cellular immunotherapy for haematological malignancies and T cell immunobiology.

She has clinical interests in paediatric malignant haematology, and leads on cell therapy and research within the department. She is a co-investigator on two CAR T cell studies for ALL, and actively involved in implementing new studies in order to improve outcomes for children with high risk or relapsed haematological malignancies.